In this episode, pediatric hematologist-oncologist Dr. Anjulika Chawla sits down with undergraduate Anisa Sharma to discuss her journey combatting sickle cell anemia through both clinical and biotech approaches. While practicing at Brown University, Chawla also leads sickle cell clinical research at bluebird bio, a Cambridge-based biotech developing gene therapies. The company’s therapy for sickle cell anemia received FDA approval this past year in December. Chawla addresses her experience shifting her focus from treating patients directly to overseeing medical research at bluebird. She also considers bluebird’s future in further improving their therapy’s impact.